Pharmaceuticals
Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development
EAST RUTHERFORD, N.J, Oct. 25, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards inBarcelona, Spain....
2023-10-25 04:18
2019
Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma
--Industry veteran to lead growth for company's CDMO and pharmaceutical supply divisions, NovaCina and LumaCina-- MIAMI and PERTH, Australia, Oct. 25, 2023 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, announced today thatCyrus K. Mirsaidi is ...
2023-10-24 23:17
1553
Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO
HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...
2023-10-24 20:00
1298
Life Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in China
First Amyloid PET Tracer Received Regulatory Approval in China BERLIN and BEIJING, Oct. 24, 2023 /PRNewswire/ -- Life Molecular Imaging (LMI) and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® (with Chinese trade name 欧韦宁®, florbetaben F-18 injection) has received regulatory appr...
2023-10-24 16:00
1533
Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval
SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "BioRay") announced onOctober 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration (FDA). This marks BioRay's first ...
2023-10-24 15:05
1235
OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product
Visit OBiO at ESGCT 30th Annual Congress in Brussels SHANGHAI, Oct. 24, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, officially announced an agreement with Refreshgene...
2023-10-24 12:05
1555
Singapore-based Juniper Biologics Awarded the Most Innovative Oncology Pharmaceutical Company 2023 by GHP Healthcare and Pharmaceutical Awards
SINGAPORE, Oct. 24, 2023 /PRNewswire/ -- Juniper Biologics
2023-10-24 12:00
1510
CCTV+: Jianchangbang Pharmacy: A Thousand Years of Tradition and Excellence
BEIJING, Oct. 24, 2023 /PRNewswire/ -- As a living legacy of Jiangxi's rich culture of traditional Chinese medicine (TCM), the respected brand, Jianchangbang Pharmacy, carries forward the splendor of Chinese medical wisdom. It is a renowned sect of theSouth China ancient TCM school and TCM prepar...
2023-10-24 11:51
1794
Based on recent data presented at 2023 ESMO, the innovative TROP2 ADC SKB264 (MK-2870) shows promising prospects for the treatment of patients with HR+/HER2- metastatic breast cancer who have undergone multiple prior lines of therapy , and its clinical development in other solid tumors is also advancing steadily
CHENGDU, China, Oct. 24, 2023 /PRNewswire/ -- Human trophoblastic cell surface antigen 2 (TROP2) exhibits high expression in numerous solid tumors, making it a prominent target in recent oncology studies. The progress in the development of Antibody-Drug Conjugates (ADCs) against this target has ...
2023-10-24 10:19
2535
Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO
* KN026 combined with docetaxel has significant efficacy in the first-line treatment of HER2-positive recurrent or metastatic breast cancer, with mPFS of 26.9 months and 24-month OS rate of 84.2%. * KN026 combined with docetaxel has significant efficacy and good tolerability in the neoadjuvan...
2023-10-24 08:41
3247
XINGIMAGING and MITRO BIOTECH CO., LTD. MERGE TO DELIVER FULL-SERVICE CRO OPERATIONS TO GLOBAL RESEARCH INITIATIVES
NEW HAVEN, Conn., Oct. 23, 2023 /PRNewswire/ -- XINGIMAGING, LLC, and MITRO Biotech Co., Ltd., two recognized lead companies offering quality and excellence in drug development and imaging solutions, have merged to create one company dedicated to providing a full spectrum of CRO & CDMO research s...
2023-10-23 22:38
1641
Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023
Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all patients treated in the expansion cohort PRINCETON, N.J. and SUZHOU, China, Oct. 23, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Tr...
2023-10-23 21:48
3976
Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis
MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ...
2023-10-23 21:30
1413
Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC
SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest clinical data of it...
2023-10-23 19:56
1309
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs
SHANGHAI, Oct. 23, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces the latest clinical progress of 2 novel drugs including Nectin-4 ADC 9MW2821, as well as the clinical study data to be reported on ESMO 2023. Latest progress...
2023-10-23 18:25
1425
The team from Kelun-Biotech held a meeting with representatives from MSD in Madrid, Spain
CHENGDU, China, Oct. 23, 2023 /PRNewswire/ -- On October 20, 2023, the European Society for Medical Oncology (ESMO) Conference grandly commenced inMadrid, Spain . The ESMO Conference is the most esteemed and influential oncology conference inEurope, and this annual event garners the participation ...
2023-10-23 18:16
1912
Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients
* Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in the 1st line setting for advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins) mutations, achieving a confirmed objective...
2023-10-23 17:34
1363
Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023
* HMBD-001 is Hummingbird Bioscience's proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials inAustralia, targeting multiple solid tumors * The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limiting toxicities and no severe treatment-re...
2023-10-23 14:23
1667
Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at JSA2023
TOKYO, Oct. 23, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a biotech company specializing in the development of treatments for allergy, asthma, nephrology, dermatology, ophthalmology and other autoimmune diseases, oral presented the phase I data of ...
2023-10-23 12:27
1919
InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023
NANJING, China, Oct 22, 2023 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome drug resistance for hard-to-treat solid tumors, announces that clinical data of Ifebemtinib (IN10018), a highly potent and selective oral i...
2023-10-23 08:00
1684
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 273 media titles]
2024-11-29 20:33
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
13411
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
9486
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8327
